NYSEARCA:KNW - NYSE Arca - US4992382022 - Common Stock - Currency: USD
0.43
+0.03 (+7.02%)
The current stock price of KNW is 0.43 USD. In the past month the price decreased by -59.05%. In the past year, price decreased by -36.89%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.56 | 228.46B | ||
ISRG | INTUITIVE SURGICAL INC | 62.66 | 171.52B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.87 | 140.59B | ||
SYK | STRYKER CORP | 28.56 | 132.87B | ||
MDT | MEDTRONIC PLC | 15.61 | 106.93B | ||
BDX | BECTON DICKINSON AND CO | 14.37 | 57.39B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.95 | 41.51B | ||
IDXX | IDEXX LABORATORIES INC | 37.47 | 34.17B | ||
RMD | RESMED INC | 24.22 | 31.44B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 13.73 | 28.23B | ||
DXCM | DEXCOM INC | 40.2 | 26.01B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.18 | 22.69B |
Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. Its patent-pending technology makes it possible to identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s expected application of the technology is focused on a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. Its sensor technology embodies two key components: hardware and software. The hardware component includes a sensor which both sends and receives a radio frequency signal. The Company’s wholly owned subsidiary is Particle, Inc.
KNOW LABS INC
619 Western Avenue, Suite 610
Seattle WASHINGTON US
Employees: 15
Company Website: https://www.knowlabs.co/
Investor Relations: http://www.knowlabs.co/investors
Phone: 12069031351
The current stock price of KNW is 0.43 USD. The price increased by 7.02% in the last trading session.
The exchange symbol of KNOW LABS INC is KNW and it is listed on the NYSE Arca exchange.
KNW stock is listed on the NYSE Arca exchange.
5 analysts have analysed KNW and the average price target is 40.8 USD. This implies a price increase of 9388.37% is expected in the next year compared to the current price of 0.43. Check the KNOW LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KNOW LABS INC (KNW) has a market capitalization of 1.21M USD. This makes KNW a Nano Cap stock.
KNOW LABS INC (KNW) currently has 15 employees.
KNOW LABS INC (KNW) has a support level at 0.4. Check the full technical report for a detailed analysis of KNW support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KNW does not pay a dividend.
KNOW LABS INC (KNW) will report earnings on 2025-05-13.
KNOW LABS INC (KNW) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.72).
ChartMill assigns a technical rating of 3 / 10 to KNW. When comparing the yearly performance of all stocks, KNW is one of the better performing stocks in the market, outperforming 98.33% of all stocks.
Over the last trailing twelve months KNW reported a non-GAAP Earnings per Share(EPS) of -3.72. The EPS decreased by -1305.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -1168.61% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to KNW. The Buy consensus is the average rating of analysts ratings from 5 analysts.